AIM
CODX

Axiom Investment Management’s Co-Diagnostics CODX Stock Holding History

Axiom Investment Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed – – 155
2022
Q3 		$0 Buy
+1
New +$140 ﹤0.01% 422

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Axiom Investment Management's CODX Position: Q4 2022 in Review

Axiom Investment Management sold out of Co-Diagnostics (CODX) in Q4 2022, closing a stake of 1 share.

Axiom Investment Management first reported a position in CODX in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 60 funds tracked by Wall St. Rank hold CODX as of Q4 2022.

  • Axiom Investment Management reported no remaining Co-Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Axiom Investment Management sold 1 Co-Diagnostics share in Q4 2022.
  • Axiom Investment Management first reported a position in Co-Diagnostics in Q3 2022 and held it in 1 quarter.
  • Axiom Investment Management's Co-Diagnostics position peaked at $0 in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2022.

Based on Axiom Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.